Item no. |
HY-13725A-10mM |
Manufacturer |
MedChem Express
|
CASRN |
95343-20-7 |
Amount |
10mM/1mL |
Quantity options |
100 mg
10mM/1mL
10 mg
50 mg
5 mg
|
Category |
|
Type |
Inhibitors |
Specific against |
other |
Purity |
98.56 |
Formula |
C32H38ClNO12 |
Citations |
Cancer Drug Resist. 2020 Sep 12. <br/>Heliyon. June 2022, e09643.<br/>Int J Pharm. 2022 May 25;620:121761.<br/>J Mol Liq. 2020, 114633.<br/>J Mol Liq. 2023 Jun 12, 122324.<br/>University of Paris. 2022 Sep 19.<br/>Cancers (Basel). 2023 Apr 26, 15(9), 2487.<br/>E3S Web of Conferences. 233, 02010 (2021).<br/>Genomics. 2021 Nov 26;S0888-7543(21)00410-9.<br/>Int J Biol Macromol. 2024 Apr 10;267(Pt 2):131514.<br/>Int J Cancer. 2024 Jul 15;155(2):324-338.<br/>Int J Hyperthermia. 2024 Feb 12;41(1):2316085.<br/>Int J Mol Med. 2023 May 17.<br/>J Mol Med (Berl). 2019 Aug;97(8):1183-1193.<br/>Mol Med Rep. 2024 May;29(5):84.<br/>Toxicol Appl Pharmacol. 2023 Feb 3;462:116411.<br/>[1]Takigawa N, et al. Cytotoxic effect of topoisomerase II inhibitors against adriamycin- and etoposide-resistant small cell lung cancer sublines. Gan To Kagaku Ryoho. 1993 May;20(7):929-35.<br/>[2]Nagai K, et al. Relationships between the in vitro cytotoxicity and transport characteristics of pirarubicin and doxorubicin in M5076 ovarian sarcoma cells, and comparison with those in Ehrlich ascites carcinoma cells. Cancer Chemother Pharmacol. 2002 Mar;49(3):244-50. Epub 2002 Jan 8.<br/>[3]Li K, et al. Pirarubicin induces an autophagic cytoprotective response through suppression of the mammalian target of rapamycin signaling pathway in human bladder cancer cells. Biochem Biophys Res Commun. 2015 May 1;460(2):380-5.<br/>[4]Wang YD, et al. Cardioprotective effects of rutin in rats exposed to pirarubicin toxicity. J Asian Nat Prod Res. 2017 Oct 27:1-13. |
Smiles |
O=C1C2=C(C=CC=C2OC)C(C3=C(O)C4=C([C@@H](O[C@@]5([H])C[C@H](N)[C@H](O[C@@]6([H])OCCCC6)[C@H](C)O5)C[C@@](C(CO)=O)(O)C4)C(O)=C31)=O.Cl |
ECLASS 10.1 |
32160490 |
ECLASS 11.0 |
32160490 |
UNSPSC |
12000000 |
Alias |
THP Hydrochloride |
Available |
|
Product Description |
Pirarubicin Hydrochloride is an anthracycline antibiotics, acts as a topoisomerase II inhibitor, and is a widely used for treatment of various cancers, in particular, solid tumors. |
StorageTemperature |
4°C (Powder, sealed storage, away from moisture and light) |
Shipping |
Room Temperature |
Manufacturers Applications |
Cancer-programmed cell death |
MolecularWeight |
664.10 |
Clinical Information |
Launched |
Manufacturers Research Area |
Cancer; Infection |
Solubility |
DMSO : 20.83 mg/mL (ultrasonic)|H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C) |
Target |
Antibiotic; Autophagy; Bacterial; Topoisomerase |
Manufacturers Target |
Antibiotic; Autophagy; Bacterial; Topoisomerase |
Isoform |
Topo II |
Manufacturers Pathway |
Anti-infection; Autophagy; Cell Cycle/DNA Damage |
Manufacturers Product type |
Reference compound |
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.